Longitudinal changes of swallowing safety and efficiency in infants with spinal muscular atrophy who received disease modifying therapies
Pediatric Pulmonology · 2024
DOI: 10.1002/ppul.26919 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pediatric Pulmonology, 2024. Verfasst von Carmen Leon-Astudillo und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, University of Florida College of Medicine, Gainesville, Florida, USA. Hauptthemen laut MEDLINE: Deglutition Disorders, Deglutition. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 29 Literaturangaben. Gefördert von: Children's Miracle Network Hospitals.
Abstract (Originalsprache)
Background
Dysphagia is a common feature of the natural history of patients with spinal muscular atrophy (SMA). Literature regarding swallowing safety and efficiency is scarce in patients with SMA, particularly in the era of newborn screening programs and disease‐modifying therapies.
Objective
To describe the longitudinal changes of swallowing safety and efficiency in children with SMA who received one or more disease modifying therapies Methods Case series of patients with SMA followed at the University of Florida from 1 May 2019 to 31 December 2022 who had two or more videofluoroscopy swallowing studies (VFSS), with the first being within 30 days of their first treatment. Data extracted from the electronic health record included: neuromotor outcomes, VFSS penetration aspiration scores (PAS), presence of abrnormal oral or pharyngeal residue, clinical history, and timing of disease‐modifying therapies administration.
Results
Seven subjects were included (five male); three were diagnosed via newborn screen. Median age at diagnosis was 10 days (range: 4–250). Median age at initial VFSS was 29 days (range: 9–246), and age at the last VFSS was 26.1 months (range: 18.2–36.2). All subjects received onasemnogene‐abeparvovec (OA); four received additional therapies. PAS at diagnosis was abnormal in four subjects. Six subjects required feeding modifications after VFSS results. Of these, three had silent aspiration (PAS 8) and three of them improved after treatment.
Conclusions
Swallowing safety and efficiency can be impaired in patients with SMA despite early treatment. Larger, prospective studies are needed to define optimal timiing of longitudinal instrumental evaluations.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pediatrics, University of Florida College of Medicine, Gainesville, Florida, USA.
- Department of Speech, Language, and Hearing Sciences, University of Florida College of Medicine, Gainesville, Florida, USA.
- Aerodigestive Research Core Laboratory, University of Florida, Gainesville, Florida, USA.
- Department of Physical Therapy, University of Florida, Gainesville, Florida, USA.
ORCID-Profile: Carmen Leon-Astudillo, Manuela Corti, Emily K Plowman, Barry J Byrne, Barbara K Smith
Förderung
- Children's Miracle Network Hospitals
Zitieren
APA
Leon-Astudillo, C., Brooks, O., Salabarria, S. M., Coker, M., Corti, M., Lammers, J., Plowman, E. K., Byrne, B. J., & Smith, B. K. (2024). Longitudinal changes of swallowing safety and efficiency in infants with spinal muscular atrophy who received disease modifying therapies. Pediatric Pulmonology. https://doi.org/10.1002/ppul.26919
Vancouver
Leon-Astudillo C, Brooks O, Salabarria SM, Coker M, Corti M, Lammers J, et al. Longitudinal changes of swallowing safety and efficiency in infants with spinal muscular atrophy who received disease modifying therapies. Pediatric Pulmonology. 2024. doi:10.1002/ppul.26919
BibTeX
@article{LeonAstudillo2024,
author = {Leon-Astudillo, Carmen and Brooks, Olivia and Salabarria, Stephanie M and Coker, Mackenzi and Corti, Manuela and Lammers, Jenna and Plowman, Emily K and Byrne, Barry J and Smith, Barbara K},
title = {Longitudinal changes of swallowing safety and efficiency in infants with spinal muscular atrophy who received disease modifying therapies},
journal = {Pediatric Pulmonology},
year = {2024},
doi = {10.1002/ppul.26919}
}
EUVIMED